Investors must purchase Zydus Lifesciences shares by Wednesday, May 27 to be eligible for the ₹1,100 crore buyback, as the record date is May 29. According to The Economic Times, the company approved buying back up to 95.65 lakh shares at ₹1,150 each, representing a 7% premium from the stock's previous closing price of ₹1,079.05. Only shareholders who own shares in their demat accounts as of the record date will be eligible to participate in the corporate action.
The buyback will be conducted via the tender route and represents the company's biggest-ever share buyback. As reported by The Economic Times, the buyback will purchase up to 95.65 lakh shares, each with a face value of Re 1, representing 0.95% of the company's paid-up equity share capital. The board of directors has approved the formation of a buyback committee that can adjust the buyback price or number of shares up to one day before the record date, without changing the overall buyback size.
Zydus Lifesciences reported robust Q4 results with consolidated net profit of ₹1,272.5 crore for the January-March quarter of FY26, marking a 9% increase from ₹1,171 crore in the corresponding quarter of the previous financial year. According to The Economic Times, the company's revenue from operations rose more than 16% year-on-year to ₹7,587 crore during the quarter, compared with ₹6,528 crore in the year-ago period. The strong performance has contributed to the company's decision to recommend a final dividend of Re 1 per share subject to shareholder approval at the Annual General Meeting scheduled for August 11.
The stock has demonstrated strong performance with gains of over 4% in one week and 15% in one month, and is up more than 18% so far in 2026. As reported by The Economic Times, the company currently has a market capitalisation of nearly ₹1.09 lakh crore. Prior to the buyback announcement, the promoter and promoter group held nearly 75% stake in the company, while retail investors and mutual funds held around 5% each. Foreign portfolio investors owned nearly 7% of the company, and insurance companies held slightly over 6%.
This follows the company's ₹600 crore share buyback conducted via the tender route at ₹1,005 per share with a 9% premium over the trading level. According to The Economic Times, prior to that, the company had executed a ₹750 crore share buyback in 2022. The current buyback represents the company's largest share repurchase program to date, offering investors a significant premium opportunity while demonstrating strong financial performance and board confidence in the company's prospects.
